ArticleThe Journal of infectious diseases2016
Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.PLoS pathogens · 2022Trial
- BACH2 promotes seeding and establishment of long-lived HIV-1 reservoir in memory CD4Cell reports. Medicine · 2025Article
- Prediction of the Co-receptor usage of the main worldwide HIV-1 subtypes, CRF, and CRF35-AD in Iranian patients via the five genotypic tools.Biochemistry and biophysics reports · 2025Article
- HIV-1 Rebound Virus Consists of a Small Number of Lineages That Entered the Reservoir Close to ART Initiation.bioRxiv : the preprint server for biology · 2025Article
- Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral Replication.Open forum infectious diseases · 2024Article
- The timing of HIV-1 infection of cells that persist on therapy is not strongly influenced by replication competency or cellular tropism of the provirus.PLoS pathogens · 2024Article
- HIV-1 tropism in low-level viral load HIV-1 infections during HAART in Guangdong, China.Frontiers in microbiology · 2023Article
- Review
- Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1.The Journal of clinical investigation · 2021Article
- The Paradox of HIV Blood-Brain Barrier Penetrance and Antiretroviral Drug Delivery Deficiencies.Trends in neurosciences · 2020Review
- Impact of fluctuation in frequency of human immunodeficiency virus/simian immunodeficiency virus reactivation during antiretroviral therapy interruption.Proceedings. Biological sciences · 2020Article
- A single variant sequencing method for sensitive and quantitative detection of HIV-1 minority variants.Scientific reports · 2020Article
- Novel Transmitted/Founder Simian-Human Immunodeficiency Viruses for Human Immunodeficiency Virus Latency and Cure Research.Journal of virology · 2020Article
- HIV-1 Latency and Latency Reversal: Does Subtype Matter?Viruses · 2019Review
- Blocking Formation of the Stable HIV Reservoir: A New Perspective for HIV-1 Cure.Frontiers in immunology · 2019Review
- Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.Journal of virology · 2018Article
- Single Genome Sequencing of Expressed and Proviral HIV-1 Envelope Glycoprotein 120 (Bio-protocol · 2017Article
- Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee.Retrovirology · 2017Article
- Prospecting for an HIV vaccine.Tropical diseases, travel medicine and vaccines · 2017Review
- Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.The New England journal of medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Human immunodeficiency virus-infected people discontinuing therapy experience a rebound in the virus level (hereafter, "rebound virus") from a persistent reservoir. We examined 10 samples from patients in AIDS Clinical Trials Group study A5068 with rebound virus, using single-genome amplification and Primer ID deep sequencing, to assess env genetic diversity of the virus population. Most rebound-virus populations showed significant diversity. All env examined required high levels of CD4 for entry, consistent with selection of replication in CD4(+) T cells. These results indicate that most people discontinuing therapy release a diverse population of virus and that this released virus has entry features of virus selected for replication in CD4(+) T cells, rather than in myeloid cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.